APA (7th ed.) Citation

MJ, D., SC, B., SL, A., P, R., D, S., MS, S., . . . GE, U. (2016). Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes care, 39(2), 222. https://doi.org/10.2337/dc14-2883

Chicago Style (17th ed.) Citation

MJ, Davies, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, Bosch-Traberg H, Syrén A, and Umpierrez GE. "Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial." Diabetes Care 39, no. 2 (2016): 222. https://doi.org/10.2337/dc14-2883.

MLA (9th ed.) Citation

MJ, Davies, et al. "Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial." Diabetes Care, vol. 39, no. 2, 2016, p. 222, https://doi.org/10.2337/dc14-2883.